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Summary Transmitted drug resistance is an emerging phenomenon with important clinical and
public health implications. It has been reported in 3.4% to 26% of HIV-infected persons in the USA.
Most cases affect non-nucleoside reverse transcriptase inhibitors or nucleos(t)ide reverse
transcriptase inhibitors. Transmitted protease inhibitor or multi-class resistance is uncommon,
occurring in <5% of cases. The genital tract may function as a reservoir of transmissible drug-
resistant variants or a site for low-level viral replication at a time plasma HIV is suppressed.
Transmitted drug-resistant HIV variants, including those that exist in very low titers (minority
populations), are associated with suboptimal virologic response to initial antiretroviral therapy.
Baseline resistance testing, preferably genotype, appears to be cost-effective and is recom-
mended for all treatment-naı¨ve patients in the USA, although prospective trials have not been
performed. It appears transmitted drug resistance is still relatively low in developing countries,
but there is a dearth of information.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
HIV resistance to antiretroviral (ARV) drugs is an evolutionary
phenomenon that favors the selection of viral strains best
adapted to survive in the prevailing environment. It is clas-
sified as primary resistance when there is no history of
antiretroviral therapy (ART), or secondary resistance when
it develops after exposure to ARV drug(s). Secondary resis-
tance is common when ART fails to achieve full suppression of
plasma HIV RNA. In the HIV-1 Cost and Services Utilization
Study (HCSUS, 1996—1999), drug resistance mutations were
present in 76% of patients who had plasma HIV RNA >500* Tel.: +1 312 6950009; fax: +1 312 6955088.
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doi:10.1016/j.ijid.2008.10.008copies/ml despite being on ART. Resistance was detected at a
higher frequency among those actively on treatment (87%)
versus those not on ARTat the time (43%).1 Although the vast
majority of patients who develop secondary drug resistance
in the USA do so while taking prescribed ART, some cases are
due to informal (non-prescribed) use of ARV drugs, such as
pill-sharing.2
Three mechanisms exist for primary HIV drug resistance.
The first is de novo resistance, exemplified by HIV-2 resis-
tance to non-nucleoside reverse transcriptase inhibitors
(NNRTIs). Of note, there are numerous polymorphisms in
subtype B and non-subtype B HIV-1 at sites where specific
mutations induce drug resistance. These polymorphisms are
different from transmitted drug resistance, although some
may serve accessory roles or provide shorter pathways to
actual drug resistance mutations. The second mechanismPublished by Elsevier Ltd. All rights reserved.
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of the high infidelity of HIV’s replication, which leads to the
daily generation of virtually every possible point mutation.
These translational errors often result in stop codons and
defective virions, but critical mutations associated with drug
resistance are possible. In the absence of selective drug
pressure, however, the emergent drug-resistant variants
may be difficult to detect with bulk population sequencing.
The third mechanism of primary resistance of HIV to ARV drugs
is transmitted resistance or infection with a drug-resistant HIV
strain. Transmitted resistance occurs with sexual,3—5 parent-
eral,6,7 and vertical8—10 routes of viral acquisition.
Zidovudine (ZDV) was the first drug found to have inhibi-
tory effects on HIV reverse transcriptase and replication in
1985. Following Federal Drug Administration (FDA) approval,
widespread use of the drug commenced in 1987, and isolates
with reduced susceptibility were first described in 1989.11
The sentinel case of transmitted resistance in 1992 involved a
ZDV-resistant 215Y variant isolated from a treatment-naı¨ve
20-year-old male who had three sex partners, one of whom
was receiving ZDV.12 Since then, the sequence of widespread
use of a class of ARV agents, followed by selection of HIV
variants that are resistant to that agent, and subsequent
transmission of the resistant variants has been reproduced
for other nucleos(t)ide reverse transcriptase inhibitors
(NRTIs), NNRTIs, protease inhibitors (PIs), and enfuvirtide,
a fusion inhibitor.13 Although there are no cases to date of
transmitted resistance involving the newest classes of FDA
approved ARV drugs (integrase inhibitors and CCR5 receptor
antagonists), this is expected to change as the drugs become
widely used. This article summarizes the US epidemiology of
transmitted ARV drug resistance in the era of combination
antiretroviral therapy (CART), and provides an overview of
the current understanding of its clinical implications as well
as practical guides for clinicians who care for these patients.
Transmitted resistance in the USA
The first studies describing the US prevalence of transmitted
HIV drug resistance in the CART era were published in Sep-
tember 1999. In one of the studies, Boden et al. evaluated 80
HIV-infected patients from large urban US cities, mainly New
York and Los Angeles.14 The patients were predominantly
(93.8%) men who have sex with men (MSM) and were recently
infected (range 0.5—5 months of initiating the study). The
prevalence of any transmitted drug resistance mutation was
16.3%, including NRTI 12.5%, NNRTI 5.7%, and PI 2.5%. There
were three isolates with genotypic and phenotypic resistance
to more than one class of ARV drugs (MDR). The second study,
by Little et al.,15 enrolled 141 subjects who had serocon-
verted within the 12 months preceding the study. This study
included six patients with prior ART (<7 days), which con-
founds the findings because secondary resistance could have
occurred in this subset. Drug susceptibility was measured in
terms of phenotypic fold-change, defined as the ratio of ARV
drug concentration required for 50% inhibition (IC50) of the
subject’s virus to the IC50 for a drug-sensitive reference virus.
Reduced susceptibility, defined as fold-change >2.5, was
demonstrated in 26% of the viral isolates (NNRTI 17%, NRTI
3%, and PI 10%). Importantly, the susceptibility cut-off of 2.5-
fold-change used in the study was arbitrary, and the study
probably overestimated transmitted resistance since thelevels of fold-change that correlate with loss of clinical
efficacy are now known to be generally higher. Only 3/141
(2%) of the isolates had fold-change >10, and these isolates
were also MDR. Later studies evaluating the prevalence of
transmitted resistance in the USA ranged from cross-sec-
tional epidemiological studies to longitudinal studies asses-
sing trends. Reported transmitted mutations include some
associated with NNRTI resistance (K103N, Y181C/I, G190S/A,
P225H, V106 M/A, L100I), NRTI resistance (M184 V, M41L,
T215F/Y, 215 partial revertants, D67N, L210W, T215D/S,
K219D, K65R), or PI resistance (M46L, L33F/V, V32I, V82A,
L90 M). Most available data are from subtype B HIV, but there
are rare cases of transmitted drug resistance involving non-
subtype B HIV.16,17
Overall, US studies have reported transmitted drug resis-
tance prevalence rates of 3.4% to 26%.14,15,17—27 This wide
range reflects the heterogeneity of the study designs, includ-
ing HIV infection stage (acute HIV, recent infection, or estab-
lished infection) and demographics of the study population,
resistance detection methodology (genotype versus pheno-
type), phenotypic or genotypic assay used, and definition of
resistance mutation. Accordingly, cross-study comparisons
are inherently erroneous. For example, studies that enroll
recently infected persons are likely to find higher prevalence
rates because transmitted resistant variants are less detect-
able over time. A few studies have reported higher rates of
transmitted resistance among MSM, compared to women,
heterosexual men, and injection drug users, and among
whites than African Americans or Hispanics.18,19 However,
a study among high-risk MSM in six major US cities found no
significant association between ARV drug resistance and
demographic factors, sexual practices, self-reported sexu-
ally transmitted infections, use of recreational drugs, or use
of HIV post-exposure prophylaxis.24 To standardize the defi-
nition of transmitted resistance for future studies, Shafer and
others were the first to propose that mutations included in
epidemiological studies of transmitted resistance should: (1)
develop in patients exposed to ARTand be a recognized cause
or contributor to resistance; (2) not occur as a polymorphism;
(3) be unambiguous; and (4) be applicable to all HIV-1 sub-
types since major resistance mutations are similar in subtype
B and non-subtype B HIV-1, although there may be differ-
ences in the resistance pathways. Using these criteria they
identified 31 PI resistance mutations, 31 NRTI resistance
mutations, and 18 NNRTI resistance mutations that should
be included in epidemiological studies (Table 1).28 Bennett
et al. recently updated the list of transmitted mutations for
surveillance studies (Table 1).29
Trends in HIV transmitted drug resistance can be influ-
enced by factors such as prevalence of drug resistance among
persons engaged in high-risk behavior, access to ART, physi-
cian prescribing practices, and proportion of HIV-infected
patients achieving full suppression of plasma viremia.30—33 In
the pre-CARTera, transmitted resistance in the USA primarily
involved NRTIs, which were the drugs in widespread use at
the time. While transmitted NRTI resistance remains impor-
tant, a shift towards more transmitted NNRTI resistance
occurred after widespread use of NNRTIs began in the
1990 s. Illustratively, transmitted NRTI resistance in parts
of North America and Europe peaked in the mid-1990 s then
fell after 1997,30 at which time a striking increase in trans-
mitted NNRTI resistance emerged. In San Francisco General
Table 1 Mutations fulfilling criteria for inclusion in
epidemiological studies of transmitted resistance28,29
NRTI M41L, K65R, 67N/G, T69D/N/ins, K70E/R,
L74I/V, V75M/T/S, Y115F, Q151M, M184V/I,
L210W, T215Y/F/C/D/E/S/I/V, K219Q/E.
NNRTI L100I, K101E/P, K103N, V106A/M, E138K,
V179F, Y181C/I/V, Y188L/C, G190A/S,
P225H, M230L, 318F
PI L23I, L24I, D30N, V32I, I47V/M, G48M/V,
I50L/V, F53L/Y, I54V/L/M/A/T/S, Q58E,
G73C/S/T/A, T74P, L76V, V82A/T/F/L/S/M/C,
N83D, I84V/A/C, 85V, N88D/S, L89V, L90M
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rose from 0% in 1996 to 6.4% in 1998—1999 and 13.2% in
2000—2001.22 Transmission of NNRTI resistance in New York
City was higher in 2003—2004 compared to 1995—1998.26
Similarly, there was a higher prevalence of transmitted NNRTI
resistance among patients who enrolled in US clinical trials in
2007 versus 2000.27 Recently infected persons, because of
their high infectiousness, probably fuel transmission of NNRTI
resistance.34,35 Major PI resistance is still uncommonly trans-
mitted (<5%) despite widespread use of these drugs.27 Trans-
mitted MDR remains rare (<2.5%), although an increase was
demonstrated in a comparison of 1996—1997 to 2000—200122
as well as between 2000 and 2007.27 It is unconfirmed that
transmitted resistance is falling in San Francisco led by a
decline in transmitted NRTI resistance.36
Viral fitness and transmissibility of drug-
resistant HIV strains
Data suggesting an association between viral fitness and
transmissibility of drug-resistant strains are weak and so
far inconclusive.37—42 For example, using complicated
assumptions and mathematical modeling of the genotypes
from HIV-infected patients in Los Angeles and San Diego,
investigators found that drug-resistant strains were trans-
mitted only 20% of the frequency predicted by the pre-
valence of drug resistance.42 Also, there is the suggestion
that transmissibility of 184 V and MDR variants, which tend
to have impaired fitness, is compromised.38—40 In contrast,
other investigators estimated the transmissibility of spe-
cific resistance mutations by calculating the ratio of the
number of recent HIV seroconverters with specific muta-
tions to the number of potential transmitters of that
mutation. In that study, strains with 41L, 215Y/F, 181C,
or 46L were more efficiently transmitted than those with
184 V, 103N, 82A/S/T, or 90 M,43 but these findings do not
fully correlate with known effects of each mutation on
viral fitness, indicating that other factors are important.
Transmitted resistance occurred more frequently in sub-
type B versus non-subtype B in the European SPREAD
Program;44 however, this more likely reflects the longer
period of ARV drug exposure among patients with subtype B
infection rather than any intrinsic transmission disadvan-
tage peculiar to non-subtype B HIV-1. In summary, the
complex interactions between fitness of drug-resistant
HIV and viral transmissibility remain to be fully elucidated,and it is unlikely that viral fitness exerts a dominant
influence by itself.
Viral compartmentalization and transmission
of drug resistance
HIVevolutionmay progress differently in plasma compared to
other anatomic compartments such as the central nervous
system and genital tract. It has been hypothesized that this
phenomenon may be mediated by differences in drug pene-
tration between compartments, as a result of which less ARV
accessible sites become predisposed to becoming reservoirs
of drug-resistant variants and low-level viral replication.45—
48 HIV proviral DNA has been detected in seminal cells,
circulating monocytes, and CD4+ T lymphocytes of patients
with suppressed plasma HIV RNA.49—54 A study comparing the
evolution of transmitted NNRTI resistance mutations in
semen-derived versus blood-derived HIV from five newly
infected persons, showed persistence of NNRTI resistance
in the semen of two individuals after full reversion of the
blood isolates to wild-type.55 In the female genital tract,
there is local production of phylogenetically distinct viral
populations with divergent mutational patterns and co-
receptor usage,47 as well as local changes in gp120 N-linked
glycosylations,45 which play an important role in conferring
escape from immune recognition.56,57 Despite these tanta-
lizing reports, however, it is premature to conclude that
significant differences exist in the composition of viruses
in various compartments, because studies to date have
had inadequate sample sizes and examined a limited number
of clones.
Persistence of transmitted drug resistance
Ghosn et al. demonstrated identical resistance mutations in
plasma and peripheral blood mononuclear cell (PBMC) DNA
of 44 individuals with recent HIV infection.58 This finding
suggests that new HIV infection is caused by a homogenous
strain that subsequently populates cellular targets and
plasma. To evaluate the persistence of transmitted resis-
tance, the investigators followed five patients who received
CART early after infection and five who did not. All five
untreated patients had persistence of the transmitted drug
resistance mutations in plasma and PBMC during 24 months
of follow-up. Two of the five patients treated with CART
achieved plasma HIV RNA suppression to <400 copies/ml,
but the transmitted drug resistance mutations remained
detectable in PBMC throughout the 24-month follow-up.
The three patients who failed to suppress plasma HIV
despite CART accumulated more resistance mutations. In
another study, six recently infected patients with trans-
mitted resistance had genotypic evidence of the trans-
mitted resistance during a median follow-up of one
year.59 Most transmitted drug-resistant variants remain
detectable in plasma for over two years.60 Thus, despite
HIV’s high replication rate, low fidelity, and formation of
heterogeneous quasispecies in established infection, trans-
mitted resistant variants remain detectable in plasma for an
extended period of time.
Drug-resistant variants in plasma are eventually displaced
by wild-type HIV if selective drug pressure is absent, but the
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event differ between transmitted versus secondary resis-
tance. For example, secondary PI resistance is difficult to
detect after 4—8 weeks of stopping ART,61 due to overgrowth
of wild-type virus, which re-emerges rapidly from latently
infected resting CD4+ T cells and other long-lived produc-
tively infected cells. In contrast, transmitted resistance
fades from plasma at a slower rate because the archived
mutation(s) in this case reflect the transmitted strain(s). In
this scenario, wild-type HIV can emerge from stepwise rever-
sion of the resistance mutation (back mutation), but this
process is slower. The partial revertants that are formed
during back mutation, however, provide a genetic imprint
of the transmitted resistance and important hindsight for
clinical management. The classic example occurs with trans-
mitted 215Y/F variants, which are resistant to ZDV, and can
undergo back-mutation to partial revertants like 215C, D, N,
and S. Garcia-Lerma and others, found such partial rever-
tants in 3.3% of 603 untreated newly infected persons,62 and
they were themost commonly detected NRTI mutations (41%)
in one of the largest US studies.18 Partial revertants shorten
the mutational steps and the time required before develop-
ment of classic resistance mutations. In the study by Garcia-
Lerma et al., ZDV-resistant 215Y mutants developed an
average of 25 days after exposure of 215C virus to ZDV and
31 days after exposure of 215D variants. This was shorter than
the 63 mean days needed for emergence of the 215Y mutants
after exposure of wild-type strains to ZDV. Importantly, the
identification of partial revertants should alert the clinician
to the possible coexistence of archived mutations that could
lead to failure of first-line therapy.63 In some cases, back
mutation leads to the emergence of viral strains with
increased fitness and possibly pathogenicity, if the infecting
strain has multiple drug resistance mutations and attenuated
fitness.64
Impact of transmitted resistance on disease
progression and response to ART
Higher CD4+ T cell counts and lower plasma HIV RNA copies/
ml (viral load) have been observed in some patients with
transmitted resistance compared to those infected with wild-
type HIV,22,65 although this is not a consistent finding.17,66 In
one study, transmitted NRTI- and PI-resistant variants were
associated with lower baseline viral loads and viral set point
compared to wild-type, whereas transmitted NNRTI resis-
tance was associated with higher levels.67 Other studies have
found no difference in viral load and CD4+ T cell counts
between patients with transmitted resistance and those
infected with wild-type.26,68,69 A few case reports have
shown rapid increase in viral load and decline in CD4+ T cell
counts following transmitted MDR strains,70,71 but there is no
proof of a causal relationship.72,73 In the Concerted Action on
Seroconversion to AIDS and Death in Europe (CASCADE) Vir-
ology Collaboration, the velocity of CD4+ T cell decline was
used to estimate the impact of transmitted resistance on the
natural course of HIV infection. After adjusting for age at
seroconversion, sex, exposure category, and presentation
during primary HIV infection (PHI), baseline CD4+ Tcell count
was higher among those with transmitted resistance. How-
ever, this group experienced a steeper CD4+ T cell countdecline in the first year of follow-up and the counts con-
verged by the second year.74
Little et al. studied 377 patients with PHI between 1995
and 2000 in 10 North American cities.20 All but one (201/202)
of the patients who received ART that was not guided by
resistance testing achieved viral suppression to<500 copies/
ml at 24 weeks; however, the median time to viral suppres-
sion increased with increasing phenotypic resistance (56 days
for those with susceptible virus defined as fold-change <2.5;
55 days for those with fold-change 2.5—10; 88 days for those
with fold-change >10). In addition, time to rebound viremia
following initial suppression was shorter among those with
high-level resistance versus those with fully susceptible
virus. Other studies have confirmed the potential for poorer
response to first-line CART among patients with transmitted
resistancemutations.73,75—78 Notably, however, the impact of
transmitted resistance on clinical outcomes can be mitigated
if resistance testing is used to guide the selection of initial
ART. Using that approach, investigators in New York found no
difference in virologic and immunologic responses between
patients infected with resistance-bearing HIV and those
infected with wild-type. The median time to full viral sup-
pression (<50 copies/ml) was 112 days among persons with
wild-type HIV compared to 114 days among those with resis-
tant strains. At the time of viral suppression, median CD4+ T
cell counts in the groups were 613 cell/mm3 and 620 cells/
mm3, respectively.26
Testing for transmitted resistance in clinical
practice
Baseline resistance testing, particularly genotypic assay, is
now recommended prior to initiating ART in the USA,79,80
preferably during PHI if the diagnosis is made at that time, or
as part of the initial evaluation of persons with established
infection, even if treatment is not yet indicated. Obtaining
the test as close to the time of infection as possible increases
the potential yield because strains with resistance-conferring
mutations can be overgrown by more replication-competent
wild-type virus over time. If there is a long hiatus (several
years) between initial resistance testing and initiation of ART,
some experts recommend repeating the test because the
patient could have acquired other resistance mutations in
the interim.79 Baseline genotyping increases quality-
adjusted life expectancy, at a cost of $23 900 per quality-
adjusted life-year gained.81 Although this cost is under the
$50 000 benchmark historically used to justify medical inter-
ventions in the USA, it is clearly unrealistic in most parts of
the world. There are concerns that the ongoing scale-up of
ART in developing countries could influence rates of trans-
mitted resistance, but the magnitude and clinical impact are
unknown.
Limitations of current resistance testing
methods
Conventional techniques for resistance testing underesti-
mate the prevalence of transmitted resistance because they
detect variants that constitute approximately 20% of the
total viral pool in the tested plasma sample. Drug-resistant
variants that exist in very low titers (minority populations)
556 B. Taiwoare missed. The gap in detection of minority variants pro-
mises to be filled by techniques such as clonal analysis,
pyrosequencing, and allele-specific polymerase chain reac-
tion (PCR) testing, techniques that are still investigational
and limited to research settings. Real-time PCR based assays
that utilize primers with specific point mutations, for exam-
ple, can identify minority variants constituting as low as 0.4%
to 2% of the viral pool in the tested sample. Another inves-
tigational approach that appears to improve detection of
resistant variants involves testing both PBMC DNA and plasma
HIV RNA in contrast to conventional testing, which involves
sequencing RNA from actively replicating plasma HIV only.82
Minority drug-resistant variants missed by conventional
testing but that were detected by more sensitive assays
include those associated with NRTIs (K70R, M41L, 215F and
M184 V), NNRTIs (K103N and Y181C), and PIs (L90 M).83—86
Importantly, such missed drug-resistant minority variants
may influence outcomes of ART. This was demonstrated in
the Centers for Disease Control and Prevention (CDC) study in
which patients who experienced virologic failure within 48
weeks of initiating an ART regimen of stavudine, abacavir,
and efavirenz were retrospectively evaluated for trans-
mitted resistance. In that study, population-based sequen-
cing detected two K103N, one Y181C, and one M184 V
transmitted mutations, but allele-specific PCR testing iden-
tified additional transmitted mutations that existed in min-
ority populations: two K103N, one Y181C, and two M184 V.
The minority drug-resistant mutants were demonstrated to
be independent predictors of virologic failure.83 Similarly, in
a sub-study of treatment-naı¨ve patients participating in
ACTG 5059, the presence of minority populations of Y181C
mutants detected by allele-specific PCR of baseline samples
was associated with a 2.5-fold increased risk of virologic
failure after adjusting for recent adherence.87
Surveillance of transmitted resistance in low
resource areas
Given the tendency of transmitted resistant variants to fade
over time, cost of resistance testing, and low likelihood that
transmitted drug resistance is substantial in areas with lim-
ited exposure to ARV drugs, the World Health Organization
(WHO) surveillance guidelines for low resource areas target
HIV-infected patients who are most likely to be recently
infected and harbor detectable levels of drug-resistant
HIV-1 variants. Mandatory criteria for identifying such per-
sons according to the guidelines include: confirmed HIV-1
infection, age <25 years, and no previous pregnancy if
female.88 The guidelines recommend that transmitted resis-
tance prevalence should be classified as <5%, 5—15%, and
>15%. Mathematical models have predicted that levels >5%
are unlikely until after 10 years of scale-up or when over 30%
of all HIV-infected people in the area are receiving ART.89
These conditions do not exist in low resource areas yet. The
upper bound of 15% was selected because experts considered
that level of transmitted resistance as an appropriate trigger
for comprehensive review of transmitted mutations in the
area and the implications on local ART regimens. Using these
criteria and testing plasma samples from approximately 50
patients in each setting, transmitted resistance has been
reported to be <5% in Gauteng Province, South Africa;Manzini-Mbabane, Swaziland; Addis Ababa, Ethiopia;
Lilongwe, Malawi; Dar es Salaam, Tanzania; Entebbe,
Uganda; and N’Djamena, Chad.90—96 Notably, transmission
of NNRTI mutations was recently classified as 5—15% in
Douala, Cameroon.89 There are no data from most low
resource settings. Ongoing surveillance studies and valida-
tion of the WHO guidelines are needed to accurately char-
acterize trends in transmitted resistance in low resource
areas.
Preventing transmitted resistance
Prevention of new HIV infections in general is essential to
curtail transmitted resistance. As such, prevention should be
incorporated into HIV treatment programs with a focus
placed on high-risk groups and acutely infected patients,
recognizing that the latter groupmay account for up to 50% of
new cases of sexual HIV transmission.97 While HIV-infected
persons are the reservoirs of transmissible drug-resistant
virus, prevention initiatives can protect them from the risks
of re-infection (superinfection) and recombination with dif-
ferent viral strains.98 Sexual HIV transmission between ser-
odiscordant heterosexual couples is rare if plasma HIV RNA is
less than 500—1500 copies/ml,99—101 underscoring the need
to suppress plasma HIV RNA to levels below 50 copies/ml in
treated patients.102
Conclusions
Transmitted HIV drug resistance is an emerging phenomenon.
Most cases affect a single class, usually NNRTIs or NRTIs, while
rare cases target PIs or are MDR. While the patterns of trans-
mitted drug resistance within the USA and other developed
countries have been examined in numerous studies, there is a
dearth of information on patterns of transmitted resistance in
the context of the scale-up of ART in developing countries.
Since transmitted drug-resistant variants can fade from
plasma over time while remaining archived in reservoirs, it
is ideal to perform baseline resistance testing as close to the
time of HIV diagnosis as possible. Further interrogation of the
relationships, if any, between transmitted resistance, viral
fitness and viral compartmentalization is needed. Finally, the
best modalities for detecting and managing transmitted drug-
resistant minority variants require further study.
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